GYRE · CIK 1124105
What Gyre Therapeutics, Inc. told the SEC could break it.
Gyre's disclosures show a business concentrated almost entirely in China at both ends. Its commercial customers are all in the PRC, and its revenue funnels through three distributors — Sinopharm (51.7% of revenue), China Resources Pharmaceutical (13.3%) and Shanghai Pharmaceuticals (11.6%) — with Sinopharm alone about 53.3% of accounts receivable. Its production is just as concentrated: 100% of its lead product ETUARY is made at its Beijing and Cangzhou facilities. That single-country footing leaves it exposed to PRC government drug-pricing policy, including NHSA volume-based procurement tenders that pressure prices, and to U.S.-China trade tensions — including a proposed 100% tariff on imported pharmaceuticals — that could disrupt its cross-border sourcing and U.S. ambitions.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- US tariffs on China imports / proposed 100% pharmaceutical tariffmedium
US-China trade tensions have produced tariffs on PRC imports, and a proposed 100% tariff on imported branded/patented pharmaceuticals (unless building US capacity) could disrupt Gyre's cross-border raw-material sourcing and US ambitions.
“In September 2025, President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing capacity, although the effective d”
SEC filing →As of 2026 - PRC healthcare pricing / NHSA centralized drug procurement (VBP tenders)low
Gyre's results depend on PRC government healthcare and pricing policy — including NHSA centralized (volume-based) drug procurement tenders that pressure prices — so ETUARY's volumes and profitability hinge on succeeding in those tender processes.
“The Company's operating results are subject to risks and uncertainties arising from changes in government healthcare policies and pricing regulations in the PRC.”
SEC filing →As of 2026
Customer concentration
- three PRC distributors = 51.7% / 13.3% / 11.6% of revenue (Sinopharm 53.3% of AR)high
Gyre's revenue is highly concentrated in three PRC distributors — Sinopharm (51.7%), China Resources Pharmaceutical (13.3%) and Shanghai Pharmaceuticals (11.6%) — with Sinopharm alone ~53.3% of accounts receivable, so loss of any would be materially adverse.
“For the year ended December 31, 2025, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately 51.7 % , 13.3 % , and 11.6 % of total revenue, respectively.”
SEC filing →As of 2026
Geographic concentration
- all customers in the PRC; 100% of ETUARY manufactured in Beijing/Cangzhou, Chinahigh
All of Gyre's commercial customers are in the PRC and 100% of its lead product ETUARY is manufactured at its Beijing and Cangzhou (Hebei) facilities, concentrating both its market and its production in China.
“Our manufacturing facilities are situated in Beijing and Cangzhou, Hebei province, in the PRC. During the year ended December 31, 2025, 100% of ETUARY® we sold was manufactured at our Beijing and Cangzhou facilities.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
China Resources Pharmaceutical Group Ltd.
“For the year ended December 31, 2025, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately 51.7 % , 13.3 % , and 11.6 % of total revenue, respectively.”
Cited →Shanghai Pharmaceuticals Holding Co., Ltd.
“For the year ended December 31, 2025, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately 51.7 % , 13.3 % , and 11.6 % of total revenue, respectively.”
Cited →Sinopharm Group Co., Ltd.
“For the year ended December 31, 2025, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately 51.7 % , 13.3 % , and 11.6 % of total revenue, respectively.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch